Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.

Lacy MQ, Dispenzieri A, Hayman SR, Kumar S, Kyle RA, Rajkumar SV, Edwards BS, Rodeheffer RJ, Frantz RP, Kushwaha SS, Clavell AL, Dearani JA, Sundt TM, Daly RC, McGregor CG, Gastineau DA, Litzow MR, Gertz MA.

J Heart Lung Transplant. 2008 Aug;27(8):823-9. doi: 10.1016/j.healun.2008.05.016. Epub 2008 Jul 3.

PMID:
18656793
2.

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.

Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M, Tassidou A, Xilouri I, Delibasi S, Psimenou E, Mellou S, Terpos E, Nanas J, Dimopoulos MA.

Haematologica. 2007 Oct;92(10):1351-8.

3.

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.

Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC.

Blood. 2007 Nov 15;110(10):3561-3. Epub 2007 Aug 2.

4.

Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, Obici L, Bradwell AR, D'Eril GM, Fogari R, Moratti R, Merlini G.

Blood. 2006 May 15;107(10):3854-8. Epub 2006 Jan 24.

5.

Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.

Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, Kumar SK, Clark R, Kyle RA, Litzow MR, Inwards DJ, Ansell SM, Micallef IM, Porrata LF, Elliott MA, Johnston PB, Greipp PR, Witzig TE, Zeldenrust SR, Russell SJ, Gastineau D, Gertz MA.

Blood. 2006 Apr 15;107(8):3378-83. Epub 2006 Jan 5.

6.

Outcome of heart transplantation in patients with amyloid cardiomyopathy.

Kpodonu J, Massad MG, Caines A, Geha AS.

J Heart Lung Transplant. 2005 Nov;24(11):1763-5.

PMID:
16297778
7.

Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis.

Gillmore JD, Goodman HJ, Lachmann HJ, Offer M, Wechalekar AD, Joshi J, Pepys MB, Hawkins PN.

Blood. 2006 Feb 1;107(3):1227-9. Epub 2005 Oct 6.

8.

Diagnosis and management of the cardiac amyloidoses.

Falk RH.

Circulation. 2005 Sep 27;112(13):2047-60. Review. No abstract available.

9.

Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis.

Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG.

Bone Marrow Transplant. 2005 Oct;36(7):597-600.

PMID:
16044137
10.

Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate.

Gertz MA, Lacy MQ, Dispenzieri A, Ansell SM, Elliott MA, Gastineau DA, Inwards DJ, Micallef IN, Porrata LF, Tefferi A, Litzow MR.

Bone Marrow Transplant. 2004 Dec;34(12):1025-31.

PMID:
15516945
11.

Cardiac transplantation for amyloid heart disease: the United Kingdom experience.

Dubrey SW, Burke MM, Hawkins PN, Banner NR.

J Heart Lung Transplant. 2004 Oct;23(10):1142-53.

PMID:
15477107
12.

Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.

Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Gertz MA.

Blood. 2004 May 15;103(10):3960-3. Epub 2004 Jan 22.

13.

High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.

Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG.

Ann Intern Med. 2004 Jan 20;140(2):85-93.

PMID:
14734330
14.

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.

Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, Hawkins PN.

Br J Haematol. 2003 Jul;122(1):78-84.

PMID:
12823348
15.

High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant.

Saba N, Sutton D, Ross H, Siu S, Crump R, Keating A, Stewart A.

Bone Marrow Transplant. 1999 Oct;24(8):853-5.

16.
17.

The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement.

Dubrey SW, Cha K, Anderson J, Chamarthi B, Reisinger J, Skinner M, Falk RH.

QJM. 1998 Feb;91(2):141-57.

PMID:
9578896
18.

A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.

Kyle RA, Gertz MA, Greipp PR, Witzig TE, Lust JA, Lacy MQ, Therneau TM.

N Engl J Med. 1997 Apr 24;336(17):1202-7.

19.

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only.

Skinner M, Anderson J, Simms R, Falk R, Wang M, Libbey C, Jones LA, Cohen AS.

Am J Med. 1996 Mar;100(3):290-8.

PMID:
8629674
20.

Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Kyle RA, Gertz MA.

Semin Hematol. 1995 Jan;32(1):45-59. No abstract available.

PMID:
7878478

Supplemental Content

Support Center